• IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option

  • May 7 2024
  • Durée: 16 min
  • Podcast

IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option

  • Résumé

  • In this podcast, Dr Edgar Lerma and Dr Dana Rizk discuss IgA nephropathy and the key data on sparsentan from the phase 3 PROTECT trial.

    Voir plus Voir moins

Ce que les auditeurs disent de IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.